bioRxivBioinformaticsPreprint
A pan-cancer interrogation of intronic polyadenylation and its association with cancer characteristics
Abstract
mRNA cleavage and polyadenylation is an integral 2-step process in the generation of protein-encoding mRNA or noncoding transcripts. More than 60% of human genes have multiple polyadenylation sites either in the 3 untranslated region (3UTR-APA) or in the intronic/exonic region, resulting in expression of isoforms with alternative polyadenylation (APA) under different physiologic conditions. The 3UTR-APAs have been extensively studied, but the biology of intronic polyadenylations (IPA) remain largely unexplored. Here we characterized the IPA profiles of 9,679 patient samples across 32 cancer types from the Cancer Genome Atlas (TCGA) cohort. Overall, we identified 22,260 detectable IPA sites; 9,014 (40.5%) occurred in all 32 cancer types and 11,676 (52.5%) occurred in 2 to 31 cancer types. By comparing tumors and their paired normal tissues, we identified 180 to 4,645 dysregulated IPAs in 132 to 2,249 genes in each of 690 patient tumors from 22 cancer types that showed consistent patterns within individual cancer types. Furthermore, across all cancer types, IPA isoforms and their gene regulation showed consistent pan-cancer patterns, and cancer types with similar histologic features were clustered at higher levels of hierarchy. We selected 2,741 genes that were consistently regulated by IPAs across cancer types, including 1,834 pan-cancer tumor-enriched and 907 tumor-depleted IPA genes. Pan-cancer tumor-enriched IPA genes were amply represented in the functional pathways such as cilium assembly and DNA damage repair. Expression of IPA isoforms in DNA damage repair genes was associated with tumor mutation burdens. Expression of IPA isoforms of tumor-enriched IPA genes was also associated with patient characteristics (e.g., sex, race, cancer stages, and subtypes) in cancer-specific and feature-specific manners. Importantly, IPA isoform expression for some genes could be a more accurate prognostic marker than gene expression (summary of all possible isoforms). In summary, our study reveals the roles and the clinical relevance of tumor-associated IPAs in cancer.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pan-cancer analysis reveals complex tumor-specific alternative polyadenylation
Zhuyi Xue, René L. Warren, … İnanç Birol·BMC GenomicsPeer-reviewed·Jul 13, 2018
- Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma
S. Venkat, A. A. Tisdale, … M. E. Feigin·bioRxiv·Aug 30, 2019
- Widespread intronic polyadenylation diversifies immune cell transcriptomes
Irtisha Singh, Shih‐Han Lee, … Christina S. Leslie·Nature CommunicationsPeer-reviewed·Apr 24, 2018
- A TP53 Intron-Derived Peptide Promotes Tumor Survival
Louis A. Cadena, Kevin Lee Luo, … Shih‐Han Lee·bioRxiv·Sep 4, 2025
- Intronic polyadenylation isoforms in the 5' part of genes constitute a source of microproteins and are involved in cell response to cisplatin
Alexandre Devaux, Iris Tanaka, … Martin Dutertre·bioRxiv·Dec 5, 2023
- A distinct class of pan cancer susceptibility genes revealed by alternative polyadenylation transcriptome wide association study
Hui Chen, Zeyang Wang, … Lei Li·Nature CommunicationsPeer-reviewed·Feb 26, 2024